Skip to main content
SpringerLink
Log in

Antineoplastics

EGFR and KRAS mutations with acquired resistance to crizotinib: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Rossing HH, et al. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. BMC Research Notes 6: 489, Jan 2013. Available from: URL: http://doi.org/10.1186/1756-0500-6-489 - Denmark

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Antineoplastics. Reactions Weekly 1515, 31 (2014). https://doi.org/10.1007/s40278-014-2726-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-014-2726-0

Search

Navigation